Medicenna Therapeutics Corp. (MDNA) Misses Q2 EPS by 1c

Medicenna Therapeutics Corp. (NASDAQ: MDNA) reported Q2 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06).

Medicenna had cash, cash equivalents, and marketable securities of $19.3 million at June 30, 2022, compared to $20.5 million at March 31, 2022. Subsequent to the quarter end Medicenna raised US$20 million by way of a public offering. Funds on hand as of June 30, 2022 plus those raised in the recent offering, we believe, are sufficient capital to execute the Company’s operations into calendar 2024 and through important upcoming catalysts described above.

For earnings history and earnings-related data on Medicenna Therapeutics Corp. (MDNA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c